{"groups":[{"description":"GVHD PROPHYLAXIS: All patients receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover.\n\nAnti-Thymocyte Globulin: Given IV\n\nBusulfan: Given IV\n\nClofarabine: Given IV\n\nFilgrastim-sndz: Given SC\n\nFludarabine: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nRituximab: Given IV\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo total body irradiation\n\nUmbilical Cord Blood Transplantation: Undergo cord blood transplant","id":"FG000","title":"Chemotherapy Plus Cord Blood Transplant"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Participant Relapsed"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants recruitment from October 2017 to May 2022 at MD Anderson Cancer Center"}